Trial Profile
Phase II Study of Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma: Hoosier Cancer Research Network LUN15-299
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Ramucirumab (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 24 Oct 2023 Planned End Date changed from 1 Jun 2023 to 9 Nov 2023.
- 06 Feb 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jun 2023.
- 01 Aug 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Dec 2022.